{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:22:38Z","timestamp":1783034558191,"version":"3.54.6"},"reference-count":190,"publisher":"Elsevier","isbn-type":[{"value":"9780128168448","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.apcsb.2019.09.001","type":"book-chapter","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T18:47:41Z","timestamp":1574794061000},"page":"65-109","source":"Crossref","is-referenced-by-count":57,"title":["Pattern recognition receptors as potential drug targets in inflammatory disorders"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13023-018-0940-1","article-title":"Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex","volume":"13","author":"Ablinger","year":"2018","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.09.001_bib2","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1086\/344893","article-title":"Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections","volume":"186","author":"Agnese","year":"2002","journal-title":"The Journal of Infectious Diseases"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nature Reviews Immunology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"issue":"6857","key":"10.1016\/bs.apcsb.2019.09.001_bib5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib189","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%","volume":"43","author":"Arany","year":"1999","journal-title":"Antiviral Research"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/infdis\/166.4.717","article-title":"A phase I study of ampligen in human immunodeficiency virus-infected subjects","volume":"166","author":"Armstrong","year":"1992","journal-title":"The Journal of Infectious Diseases"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000362553","article-title":"A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma","volume":"164","author":"Aryan","year":"2014","journal-title":"International Archives of Allergy and Immunology"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/ACI.0000000000000212","article-title":"Toll-like receptors as targets for allergen immunotherapy","volume":"15","author":"Aryan","year":"2015","journal-title":"Current Opinion in Allergy and Clinical Immunology"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib10","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","article-title":"Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis","volume":"10","author":"Atreya","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.09.001_bib11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.dld.2018.06.010","article-title":"Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis","volume":"50","author":"Atreya","year":"2018","journal-title":"Digestive and Liver Disease"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1084\/jem.20051782","article-title":"TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis","volume":"202","author":"Bafica","year":"2005","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2016.09.015","article-title":"IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis","volume":"174","author":"Balak","year":"2017","journal-title":"Clinical Immunology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib14","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/17425255.2011.558190","article-title":"Eritoran tetrasodium (E5564) treatment for sepsis: Review of preclinical and clinical studies","volume":"7","author":"Barochia","year":"2011","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-med-052814-023338","article-title":"Importance of nucleic acid recognition in inflammation and autoimmunity","volume":"67","author":"Barrat","year":"2016","journal-title":"Annual Review of Medicine"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib16","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/eji.200737815","article-title":"Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms","volume":"37","author":"Barrat","year":"2007","journal-title":"European Journal of Immunology"},{"issue":"16","key":"10.1016\/bs.apcsb.2019.09.001_bib17","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2012.12.1561","article-title":"The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma","volume":"131","author":"Beeh","year":"2013","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"23","key":"10.1016\/bs.apcsb.2019.09.001_bib19","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1073\/pnas.0603245103","article-title":"The dsRNA binding site of human Toll-like receptor 3","volume":"103","author":"Bell","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2036.2011.04745.x","article-title":"Randomised clinical trial: Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV","volume":"34","author":"Bergmann","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.humimm.2013.08.285","article-title":"Increased Toll-like receptor 9 expression by B cells from inflammatory bowel disease patients","volume":"74","author":"Berkowitz","year":"2013","journal-title":"Human Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1021\/acs.jmedchem.5b01647","article-title":"Discovery of 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a highly potent and selective intranasal toll-like receptor 7 agonist for the treatment of asthma","volume":"59","author":"Biggadike","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.immuni.2010.03.012","article-title":"Intracellular toll-like receptors","volume":"32","author":"Blasius","year":"2010","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.09.001_bib24","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/j.1398-9995.2009.02315.x","article-title":"Nod1, Nod2 and Nalp3 receptors, new potential targets in treatment of allergic rhinitis?","volume":"65","author":"Bogefors","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib25","first-page":"104192","article-title":"Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists","author":"Bourquin","year":"2019","journal-title":"Pharmacological Research"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fimmu.2013.00317","article-title":"Comparative genomic and sequence analysis provides insight into the molecular functionality of NOD1 and NOD2","volume":"4","author":"Boyle","year":"2013","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/pr.114.009928","article-title":"International union of basic and clinical pharmacology. XCVI. Pattern recognition receptors in health and disease","volume":"67","author":"Bryant","year":"2015","journal-title":"Pharmacological Reviews"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-fc fusion protein in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib29","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/ibd.21282","article-title":"Toll-like receptors in inflammatory bowel diseases: A decade later","volume":"16","author":"Cario","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib30","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/IAI.68.12.7010-7017.2000","article-title":"Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease","volume":"68","author":"Cario","year":"2000","journal-title":"Infection and Immunity"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib31","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/all.12663","article-title":"CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study","volume":"70","author":"Casale","year":"2015","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib32","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4049\/jimmunol.1102977","article-title":"TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-\u03b1 levels","volume":"189","author":"Chamberlain","year":"2012","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.pathol.4.110807.092239","article-title":"NOD-like receptors: Role in innate immunity and inflammatory disease","volume":"4","author":"Chen","year":"2009","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fimmu.2018.00227","article-title":"C-type lectin-like receptors as emerging Orchestrators of sterile inflammation represent potential therapeutic targets","volume":"9","author":"Chiffoleau","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib35","series-title":"Phase 1B dose-escalation study OF SD-101, a novel therapeutic TLR-9 agonist, IN treatment-naive chronic hepatitis C patients","author":"Cianciara","year":"2010"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/erv.10.162","article-title":"Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: A review of HEPLISAV\u2122 safety and efficacy","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1034\/j.1398-9995.2001.056006498.x","article-title":"A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections","volume":"56","author":"Drachenberg","year":"2001","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cea.12974","article-title":"Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial","volume":"47","author":"Ellis","year":"2017","journal-title":"Clinical and Experimental Allergy"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/imm.12677","article-title":"Understanding the regulation of pattern recognition receptors in inflammatory diseases - a 'Nod' in the right direction","volume":"150","author":"Feerick","year":"2017","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-065X.2008.00734.x","article-title":"Function of Nod-like receptors in microbial recognition and host defense","volume":"227","author":"Franchi","year":"2009","journal-title":"Immunological Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ibd.21339","article-title":"Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases","volume":"17","author":"Frank","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib43","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ni.f.212","article-title":"Interstitial leukocyte migration and immune function","volume":"9","author":"Friedl","year":"2008","journal-title":"Nature Immunology"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd.2016.39","article-title":"Resolution of inflammation: A new therapeutic frontier","volume":"15","author":"Fullerton","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib45","series-title":"RO7020531, a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers","author":"Gane","year":"2018"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrd2783","article-title":"Unleashing the therapeutic potential of NOD-like receptors","volume":"8","author":"Geddes","year":"2009","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib47","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/embo-reports\/kve155","article-title":"CARD4\/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri","volume":"2","author":"Girardin","year":"2001","journal-title":"EMBO Reports"},{"issue":"43","key":"10.1016\/bs.apcsb.2019.09.001_bib49","doi-asserted-by":"crossref","first-page":"41702","DOI":"10.1074\/jbc.M307198200","article-title":"Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2","volume":"278","author":"Girardin","year":"2003","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00011-015-0873-2","article-title":"Biological effects and clinical efficacy of a topical toll-like receptor 7 agonist in seasonal allergic rhinitis: A parallel group controlled phase IIa study","volume":"64","author":"Greiff","year":"2015","journal-title":"Inflammation Research"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1465-9921-13-53","article-title":"Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis","volume":"13","author":"Greiff","year":"2012","journal-title":"Respiratory Research"},{"issue":"13","key":"10.1016\/bs.apcsb.2019.09.001_bib52","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1084\/jem.20131044","article-title":"RNA recognition by human TLR8 can lead to autoimmune inflammation","volume":"210","author":"Guiducci","year":"2013","journal-title":"Journal of Experimental Medicine"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: Mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.171.3.1393","article-title":"Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation","volume":"171","author":"Gursel","year":"2003","journal-title":"The Journal of Immunology"},{"issue":"19","key":"10.1016\/bs.apcsb.2019.09.001_bib55","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","article-title":"Antibodies to DNA","volume":"338","author":"Hahn","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1016\/bs.apcsb.2019.09.001_bib56","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.febslet.2005.07.024","article-title":"Regulation of Nod1 by Hsp90 chaperone complex","volume":"579","author":"Hahn","year":"2005","journal-title":"FEBS Letters"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib57","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/ni.2369","article-title":"C-type lectin receptors orchestrate antifungal immunity","volume":"13","author":"Hardison","year":"2012","journal-title":"Nature Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.emboj.7601962","article-title":"A critical role of RICK\/RIP2 polyubiquitination in Nod-induced NF-kappaB activation","volume":"27","author":"Hasegawa","year":"2008","journal-title":"The EMBO Journal"},{"issue":"6832","key":"10.1016\/bs.apcsb.2019.09.001_bib59","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/35074106","article-title":"The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5","volume":"410","author":"Hayashi","year":"2001","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib60","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41590-018-0188-x","article-title":"RIP kinases as modulators of inflammation and immunity","volume":"19","author":"He","year":"2018","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/AAC.37.3.429","article-title":"Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers","volume":"37","author":"Hendrix","year":"1993","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/icb.2016.24","article-title":"Epigenetics and innate immunity: The 'unTolld' story","volume":"94","author":"Hennessy","year":"2016","journal-title":"Immunology & Cell Biology"},{"issue":"30","key":"10.1016\/bs.apcsb.2019.09.001_bib63","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.vaccine.2013.04.063","article-title":"Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers","volume":"31","author":"Hopkins","year":"2013","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/bs.apcsb.2019.09.001_bib64","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","article-title":"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults","volume":"34","author":"Hopkins","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1517\/13543784.2011.583237","article-title":"VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis","volume":"20","author":"Horak","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"22","key":"10.1016\/bs.apcsb.2019.09.001_bib66","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1073\/pnas.0802726105","article-title":"A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide","volume":"105","author":"Hsu","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib67","first-page":"393","article-title":"[The expression of NOD1 and NOD2 and the regulation of glucocorticoids on them in allergic rhinitis]","volume":"27","author":"Hu","year":"2013","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"issue":"6837","key":"10.1016\/bs.apcsb.2019.09.001_bib68","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib69","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1572-0241.2007.01149.x","article-title":"Prevalence of CARD15\/NOD2 mutations in Caucasian healthy people","volume":"102","author":"Hugot","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(15)00354-0","article-title":"Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: A single-centre, double-blind, randomised, controlled phase 2b\/3 trial","volume":"16","author":"Hung","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"issue":"19","key":"10.1016\/bs.apcsb.2019.09.001_bib71","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.biochem.74.082803.133347","article-title":"NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease","volume":"74","author":"Inohara","year":"2005","journal-title":"Annual Review of Biochemistry"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib73","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1074\/jbc.M009728200","article-title":"Human Nod1 confers responsiveness to bacterial lipopolysaccharides","volume":"276","author":"Inohara","year":"2001","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib74","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1074\/jbc.C200673200","article-title":"Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease","volume":"278","author":"Inohara","year":"2003","journal-title":"Journal of Biological Chemistry"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cpt.938","article-title":"First-in-Human study with the inhaled TLR9 oligonucleotide agonist AZD1419 results in interferon responses in the lung, and is safe and well-tolerated","volume":"104","author":"Jackson","year":"2018","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib76","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/bs.apcsb.2019.09.001_bib77","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1021\/jm401841p","article-title":"Nucleotide-binding oligomerization domain (NOD) inhibitors: A rational approach toward inhibition of NOD signaling pathway","volume":"57","author":"Jakopin","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib78","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib79","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/jid.2013.57","article-title":"A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis","volume":"133","author":"Jiang","year":"2013","journal-title":"Journal of Investigative Dermatology"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib190","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.24809","article-title":"SB9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants","volume":"89","author":"Jones","year":"2017","journal-title":"Journal of Medical Virology"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib80","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nri3875","article-title":"Translating nucleic acid-sensing pathways into therapies","volume":"15","author":"Junt","year":"2015","journal-title":"Nature Reviews Immunology"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib81","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.immuni.2009.09.018","article-title":"Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer","volume":"31","author":"Kang","year":"2009","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib82","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.immuni.2007.10.002","article-title":"Intracellular NOD-like receptors in host defense and disease","volume":"27","author":"Kanneganti","year":"2007","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ni1303","article-title":"Innate immune recognition of viral infection","volume":"7","author":"Kawai","year":"2006","journal-title":"Nature Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib84","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nature Immunology"},{"issue":"5\u20136","key":"10.1016\/bs.apcsb.2019.09.001_bib85","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cytogfr.2011.09.003","article-title":"NOD-like receptors and the innate immune system: Coping with danger, damage and death","volume":"22","author":"Kersse","year":"2011","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib86","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/IAI.72.3.1487-1495.2004","article-title":"Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors","volume":"72","author":"Kim","year":"2004","journal-title":"Infection and Immunity"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib87","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/rccm.201609-1830OC","article-title":"Role for NLRP3 inflammasome-mediated, IL-1\u03b2-dependent responses in severe, steroid-resistant asthma","volume":"196","author":"Kim","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib88","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/art.39544","article-title":"Identification of a novel toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation","volume":"68","author":"Kim","year":"2016","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib89","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.4049\/jimmunol.1001854","article-title":"Cutting edge: Crohn's disease-associated Nod2 mutation limits production of proinflammatory cytokines to protect the host from Enterococcus faecalis-induced lethality","volume":"187","author":"Kim","year":"2011","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib90","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3349\/ymj.2016.57.1.5","article-title":"NOD-like receptors in infection, immunity, and diseases","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Medical Journal"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib91","series-title":"IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trials","author":"Kimball","year":"2013"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib92","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1365-2222.2011.03783.x","article-title":"Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: A phase IIb study","volume":"41","author":"Klimek","year":"2011","journal-title":"Clinical and Experimental Allergy"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib93","series-title":"olt1177\u2122, an oral nlrp3 inflammasome inhibitor, inhibits acute joint inflammation and circulating il-1\u03b2 during gout flares in humans","author":"Kl\u00fcck","year":"2020"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib94","doi-asserted-by":"crossref","first-page":"e0161313","DOI":"10.1371\/journal.pone.0161313","article-title":"Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the Woodchuck model of chronic hepatitis B","volume":"11","author":"Korolowicz","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.09.001_bib95","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/jamadermatol.2014.794","article-title":"Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: A randomized clinical trial","volume":"150","author":"Kumar","year":"2014","journal-title":"JAMA Dermatology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib96","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-230X-14-79","article-title":"Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients","volume":"14","author":"Kuznetsov","year":"2014","journal-title":"BMC Gastroenterology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib97","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib98","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","volume":"20","author":"Lawitz","year":"2015","journal-title":"Antiviral Therapy"},{"issue":"6881","key":"10.1016\/bs.apcsb.2019.09.001_bib99","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"issue":"47","key":"10.1016\/bs.apcsb.2019.09.001_bib100","doi-asserted-by":"crossref","first-page":"39800","DOI":"10.1074\/jbc.M112.410027","article-title":"Proteasomal degradation of Nod2 protein mediates tolerance to bacterial cell wall components","volume":"287","author":"Lee","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib101","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.addr.2013.05.007","article-title":"Targeting C-type lectin receptors with multivalent carbohydrate ligands","volume":"65","author":"Lepenies","year":"2013","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib102","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3851\/IMP2548","article-title":"Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist","volume":"18","author":"Lopatin","year":"2013","journal-title":"Antiviral Therapy"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib103","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1128\/IAI.70.9.4892-4896.2002","article-title":"Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide","volume":"70","author":"Lorenz","year":"2002","journal-title":"Infection and Immunity"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib104","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molimm.2014.05.001","article-title":"Increased expression of toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: Ethnic differences and potential new targets for therapeutic drugs","volume":"61","author":"Lyn-Cook","year":"2014","journal-title":"Molecular Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0033-8389(02)00117-3","article-title":"Classification of small bowel Crohn's subtypes based on multimodality imaging","volume":"41","author":"Maglinte","year":"2003","journal-title":"Radiologic Clinics of North America"},{"issue":"7351","key":"10.1016\/bs.apcsb.2019.09.001_bib106","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10208","article-title":"Intestinal homeostasis and its breakdown in inflammatory bowel disease","volume":"474","author":"Maloy","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmb.2006.09.067","article-title":"Solution structure of NOD1 CARD and mutational analysis of its interaction with the CARD of downstream kinase RICK","volume":"365","author":"Manon","year":"2007","journal-title":"Journal of Molecular Biology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib108","first-page":"E1530","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib109","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis Research and Therapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.it.2005.06.004","article-title":"NLRs join TLRs as innate sensors of pathogens","volume":"26","author":"Martinon","year":"2005","journal-title":"Trends in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/mol.110.068064","article-title":"TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules","volume":"79","author":"Matsunaga","year":"2011","journal-title":"Molecular Pharmacology"},{"issue":"23","key":"10.1016\/bs.apcsb.2019.09.001_bib112","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7203","key":"10.1016\/bs.apcsb.2019.09.001_bib113","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib114","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1097-2765(00)80136-7","article-title":"MyD88 is an adaptor protein in the hToll\/IL-1 receptor family signaling pathways","volume":"2","author":"Medzhitov","year":"1998","journal-title":"Molecular Cell"},{"issue":"50","key":"10.1016\/bs.apcsb.2019.09.001_bib115","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.vaccine.2014.01.096","article-title":"Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)","volume":"32","author":"Minang","year":"2014","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/bs.apcsb.2019.09.001_bib116","doi-asserted-by":"crossref","first-page":"18987","DOI":"10.1074\/jbc.M114.557686","article-title":"The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease","volume":"289","author":"Mohanan","year":"2014","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","author":"Motwani","year":"2019","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib118","series-title":"A phase 1, multi-center, randomized, placebo-controlled, dose-escalation study OF IMO-2125, a TLR9 agonist, IN hepatitis C-nonresponders","author":"Muir","year":"2010"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib119","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1124\/jpet.102.044487","article-title":"Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist","volume":"304","author":"Mullarkey","year":"2003","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib121","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1248\/bpb.28.886","article-title":"Tissue-specific mRNA expression profiles of human toll-like receptors and related genes","volume":"28","author":"Nishimura","year":"2005","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib122","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1471-4906(03)00115-7","article-title":"The Toll-IL-1 receptor adaptor family grows to five members","volume":"24","author":"O'Neill","year":"2003","journal-title":"Trends in Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib123","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1074\/jbc.M008072200","article-title":"Nod2, a Nod1\/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB","volume":"276","author":"Ogura","year":"2001","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib124","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/gut.52.11.1591","article-title":"Expression of NOD2 in Paneth cells: A possible link to Crohn's ileitis","volume":"52","author":"Ogura","year":"2003","journal-title":"Gut"},{"issue":"48","key":"10.1016\/bs.apcsb.2019.09.001_bib125","doi-asserted-by":"crossref","first-page":"40611","DOI":"10.1074\/jbc.M112.404608","article-title":"Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I","volume":"287","author":"Ohto","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib126","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1038\/cti.2016.26","article-title":"Targeted therapeutics in SLE: Emerging strategies to modulate the interferon pathway","volume":"5","author":"Oon","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"42","key":"10.1016\/bs.apcsb.2019.09.001_bib127","first-page":"E4478","article-title":"Human TLR10 is an anti-inflammatory pattern-recognition receptor","volume":"111","author":"Oosting","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib128","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial","volume":"309","author":"Opal","year":"2013","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib129","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4049\/jimmunol.176.1.484","article-title":"Listeria monocytogenes activated p38 MAPK and induced IL-8 secretion in a nucleotide-binding oligomerization domain 1-dependent manner in endothelial cells","volume":"176","author":"Opitz","year":"2006","journal-title":"The Journal of Immunology"},{"issue":"42","key":"10.1016\/bs.apcsb.2019.09.001_bib130","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1016\/j.vaccine.2014.07.078","article-title":"Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans","volume":"32","author":"Overton","year":"2014","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib131","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.4049\/jimmunol.178.4.2380","article-title":"RICK\/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs","volume":"178","author":"Park","year":"2007","journal-title":"The Journal of Immunology"},{"issue":"5396","key":"10.1016\/bs.apcsb.2019.09.001_bib132","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: Mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib133","doi-asserted-by":"crossref","DOI":"10.1111\/exd.13979","article-title":"Epidermolysis bullosa: Advances in research and treatment","author":"Prodinger","year":"2019","journal-title":"Experimental Dermatology"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib134","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s000110050511","article-title":"The lps locus: Genetic regulation of host responses to bacterial lipopolysaccharide","volume":"48","author":"Qureshi","year":"1999","journal-title":"Inflammation Research"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib135","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","article-title":"A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis","volume":"38","author":"Rice","year":"2010","journal-title":"Critical Care Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib136","doi-asserted-by":"crossref","first-page":"e96737","DOI":"10.1371\/journal.pone.0096737","article-title":"Identification of selective small molecule inhibitors of the nucleotide-binding oligomerization domain 1 (NOD1) signaling pathway","volume":"9","author":"Rickard","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib137","doi-asserted-by":"crossref","first-page":"e69619","DOI":"10.1371\/journal.pone.0069619","article-title":"Identification of benzimidazole diamides as selective inhibitors of the nucleotide-binding oligomerization domain 2 (NOD2) signaling pathway","volume":"8","author":"Rickard","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.09.001_bib138","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1073\/pnas.95.2.588","article-title":"A family of human receptors structurally related to Drosophila Toll","volume":"95","author":"Rock","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"25","key":"10.1016\/bs.apcsb.2019.09.001_bib139","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","article-title":"Clinical practice. Chronic hepatitis C infection","volume":"364","author":"Rosen","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/iid3.91","article-title":"VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs","volume":"4","author":"Royer","year":"2016","journal-title":"Immunity, Inflammation and Disease"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib141","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/JVI.79.6.3350-3357.2005","article-title":"Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression","volume":"79","author":"Rudd","year":"2005","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib142","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.gde.2004.04.004","article-title":"Molecular genetics of Crohn's disease","volume":"14","author":"Russell","year":"2004","journal-title":"Current Opinion in Genetics & Development"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib143","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2133.2009.09210.x","article-title":"Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: An open-label, noncomparative study","volume":"161","author":"Saiag","year":"2009","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib144","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3389\/fimmu.2019.00725","article-title":"Poly-iclc, a TLR3 agonist, induces transient innate immune responses in patients with treated HIV-infection: A randomized double-blinded placebo controlled trial","volume":"10","author":"Saxena","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JAA.S17784","article-title":"Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics","volume":"4","author":"Scichilone","year":"2011","journal-title":"Journal of Asthma and Allergy"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib146","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: A review","volume":"6","author":"Shao","year":"2015","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib147","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2008.06.001","article-title":"NOD-like receptors (NLRs): Bona fide intracellular microbial sensors","volume":"20","author":"Shaw","year":"2008","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/317655","article-title":"Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997","volume":"183","author":"Shay","year":"2001","journal-title":"The Journal of Infectious Diseases"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib149","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.189.11.1777","article-title":"MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4","volume":"189","author":"Shimazu","year":"1999","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib150","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mib.2017.11.004","article-title":"C-type lectin receptors in anti-fungal immunity","volume":"40","author":"Shiokawa","year":"2017","journal-title":"Current Opinion in Microbiology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib151","doi-asserted-by":"crossref","first-page":"a000414","DOI":"10.1101\/cshperspect.a000414","article-title":"The bacterial cell envelope","volume":"2","author":"Silhavy","year":"2010","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib152","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jaci.2017.06.027","article-title":"Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study","volume":"141","author":"Silkoff","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib153","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/gut.2007.142588","article-title":"Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease","volume":"57","author":"Simms","year":"2008","journal-title":"Gut"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib154","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib155","doi-asserted-by":"crossref","first-page":"e84634","DOI":"10.1371\/journal.pone.0084634","article-title":"Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation","volume":"8","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib156","doi-asserted-by":"crossref","first-page":"e0169631","DOI":"10.1371\/journal.pone.0169631","article-title":"Antiviral efficacy and host immune response induction during sequential treatment with SB 9200 followed by entecavir in Woodchucks","volume":"12","author":"Suresh","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.09.001_bib157","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.0400525101","article-title":"Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection","volume":"101","author":"Tabeta","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib158","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2008.01.061","article-title":"Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling","volume":"368","author":"Tanimura","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"39","key":"10.1016\/bs.apcsb.2019.09.001_bib159","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1016\/j.vaccine.2012.06.086","article-title":"Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response","volume":"30","author":"Taylor","year":"2012","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/bs.apcsb.2019.09.001_bib160","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/j.vaccine.2011.05.001","article-title":"Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)","volume":"29","author":"Taylor","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib161","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00003246-199711000-00006","article-title":"Tissue factor and thrombin in posttraumatic systemic inflammatory response syndrome","volume":"25","author":"Taylor","year":"1997","journal-title":"Critical Care Medicine"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib162","series-title":"SB 9200, A novel immunomodulator for patients with viral hepatitis: Phase 1 mad study in patients with hepatitis c virus (HCV) infection","author":"Thompson","year":"2015"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib163","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/CCM.0b013e3181b07b78","article-title":"Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis","volume":"38","author":"Tidswell","year":"2010","journal-title":"Critical Care Medicine"},{"issue":"23","key":"10.1016\/bs.apcsb.2019.09.001_bib164","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1101\/gad.1964410","article-title":"Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses","volume":"24","author":"Tigno-Aranjuez","year":"2010","journal-title":"Genes & Development"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib165","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2008.02.005","article-title":"The NLR gene family: A standard nomenclature","volume":"28","author":"Ting","year":"2008","journal-title":"Immunity"},{"issue":"52","key":"10.1016\/bs.apcsb.2019.09.001_bib166","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1016\/j.vaccine.2010.10.009","article-title":"Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults","volume":"28","author":"Treanor","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.09.001_bib167","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/cpt.157","article-title":"Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement","volume":"98","author":"Tsitoura","year":"2015","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"22","key":"10.1016\/bs.apcsb.2019.09.001_bib168","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"32","key":"10.1016\/bs.apcsb.2019.09.001_bib169","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1016\/j.vaccine.2011.05.041","article-title":"Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults","volume":"29","author":"Turley","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib170","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ni.1622","article-title":"Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5","volume":"9","author":"Uematsu","year":"2008","journal-title":"Nature Immunology"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib171","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nri3325","article-title":"The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling","volume":"12","author":"Vandenabeele","year":"2012","journal-title":"Nature Reviews Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.09.001_bib172","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1684\/ecn.2013.0343","article-title":"Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level","volume":"24","author":"Verma","year":"2013","journal-title":"European Cytokine Network"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.09.001_bib173","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.09.001_bib174","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.09.001_bib175","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(03)00323-6","article-title":"Activation of autoreactive B cells by CpG dsDNA","volume":"19","author":"Viglianti","year":"2003","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.09.001_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.019","article-title":"Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2\/3 randomized, placebo-controlled, double-blind clinical trial","volume":"78","author":"Wally","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib177","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-8-69","article-title":"Topical diacerein for epidermolysis bullosa: A randomized controlled pilot study","volume":"8","author":"Wally","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib178","series-title":"Effects of SB9200 (Inarigivir) therapy on immune responses in patients with chronic hepatitis B","author":"Walsh","year":"2018"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib179","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4161\/gmic.2.1.15162","article-title":"Activation of type I IFN signaling by NOD1 mediates mucosal host defense against Helicobacter pylori infection","volume":"2","author":"Watanabe","year":"2011","journal-title":"Gut Microbes"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.09.001_bib180","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1136\/gut.2003.032805","article-title":"NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression","volume":"53","author":"Wehkamp","year":"2004","journal-title":"Gut"},{"issue":"50","key":"10.1016\/bs.apcsb.2019.09.001_bib181","doi-asserted-by":"crossref","first-page":"18129","DOI":"10.1073\/pnas.0505256102","article-title":"Reduced Paneth cell alpha-defensins in ileal Crohn's disease","volume":"102","author":"Wehkamp","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.09.001_bib182","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/all.13478","article-title":"Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy","volume":"73","author":"Worm","year":"2018","journal-title":"Allergy"},{"issue":"5633","key":"10.1016\/bs.apcsb.2019.09.001_bib183","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib184","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3389\/fimmu.2018.01027","article-title":"Dual role of toll-like receptors in human and experimental asthma models","volume":"9","author":"Zakeri","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2019.09.001_bib185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2013.00333","article-title":"Functions of NOD-like receptors in human diseases","volume":"4","author":"Zhong","year":"2013","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib186","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/08916934.2013.798651","article-title":"A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW\/F1 mice","volume":"46","author":"Zhu","year":"2013","journal-title":"Autoimmunity"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.09.001_bib187","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/imt-2018-0004","article-title":"Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy","volume":"10","author":"Zielen","year":"2018","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.09.001_bib188","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1753425910394002","article-title":"Mutational analysis of human NOD1 and NOD2 NACHT domains reveals different modes of activation","volume":"18","author":"Zurek","year":"2012","journal-title":"Innate Immunity"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Inflammatory Disorders, Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162319300665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162319300665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:17:56Z","timestamp":1761754676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162319300665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128168448"],"references-count":190,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2019.09.001","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}